Galsulfase
CAS 368590-21-0 1 FDA-DMF supplierBiologic
Overview
Galsulfase is an enzyme replacement therapy for patients with Mucopolysaccharidosis VI (MPS VI), a lysosomal storage disorder caused by the deficiency of the enzyme N-acetylgalactosamine 4-sulfatase. It helps reduce glycosaminoglycans (GAGs) accumulation in tissues and improve walking and stair-climbing capacity.
Therapeutic areas
Lysosomal Storage Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.